GOSS
NASD Gossamer Bio, Inc.$10.71 ↑ +0.00 (+0.00%) Trading Up from the previous close of $10.71, $0.48 below the day’s high of $11.19
- YTD change
- -95.68%
- vs 20-day SMA
- -8.38%
- vs 200-day SMA
- -83.74%
Price ranges
Price & Performance
+10.36 (+2996.27%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.5% away from all-time highs of $2,171.98
- GOSS is down 96% since the beginning of the year
- GOSS is down 95% over the past 12 months
- GOSS is down 22% over the past 1 month
- 15% of all GOSS investors are betting against GOSS
GOSS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +316.7%.
- Previous minute
- +$0.00
- Last hour
- -$0.22
- Last 5 days
- -2.01%
- vs 8-day SMA
- -5.25%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
